# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-14T15:34:38.922350

---

**Idea Fidelity**

The manuscript closely follows the original idea manifest. It exploits the staggered adoption of minimum unit pricing (MUP) in Scotland (2018) and Wales (2020) with England as a never-treated comparison, measures alcohol-specific mortality based on ICD-10 K70 and related codes at country and regional levels, and implements both TWFE and Callaway–Sant’Anna staggered DiD estimators. The empirical focus on alcoholic liver disease mortality, the use of England’s deprivation gradient as a distributional counterfactual, and the emphasis on robustness checks (event study, placebo outcome, COVID window, synthetic control) align with the manifest’s stated research question, data sources, and identification strategy. All key elements—staggered DiD, external control, falsification exercises, and heterogeneity—are present.

---

**Summary**

The paper estimates the causal effect of Scotland’s and Wales’s MUP policies on alcohol-specific mortality using a staggered DiD set-up with England as the never-treated control. The author reports a preferred regional TWFE estimate of −2.1 deaths per 100,000 and a Callaway–Sant’Anna ATT of −1.1 per 100,000, with event-study evidence supporting parallel trends and placebo outcomes ruling out general mortality shocks. The results are interpreted in light of the widening deprivation gradient in England, suggesting that MUP saved lives and mitigated health inequality among heavy drinkers.

---

**Essential Points**

1. **Limited Credibility of Synthetic Control Results and Interpretation**: The synthetic control exercise yields a post-treatment gap of +2.2 (Scotland worse than its synthetic counterpart) with a high permutation p-value. The text dismisses this result primarily due to poor pre-fit, but the manuscript never quantifies how bad the match is nor reconciles this with the DiD finding. The contrasting directions between DiD and synthetic control are concerning; the authors should either improve the donor pool or explain why the synthetic control can be safely disregarded (e.g., through pre-period MSPE comparisons and placebo distributions). Without such clarification, readers may suspect that the DiD result is driven by level differences between Scotland and England that the synthetic control highlights.

2. **Event Study Reference Year Choices and Pre-trend Interpretation**: Using 2017 and 2019 as reference years for Scotland and Wales respectively introduces asymmetry in the event study. More importantly, the pre-period coefficients for Scotland (2013–2016) are not close to zero and suggest structural level differences over time. While the F-test fails to reject parallel trends, the event study still shows non-zero coefficients in each pre-treatment year, raising concerns about the reliability of the parallel-trends assumption. The authors should present alternative event-study specifications (e.g., normalizing to the 2013–2017 average, differencing) to show robustness of the parallel-trends claim, and provide more detail on the F-test (degrees of freedom, null being equal linear trends) to convince readers that the assumption holds.

3. **Wales Treatment Confounded by COVID and Short Post-period**: The inclusion of Wales in the main ATT blurs interpretation, because Wales’s MUP implementation coincides with the onset of COVID, and the post-treatment window (2020–2023) is short and heavily confounded. The paper acknowledges this but still aggregates Wales with Scotland in the preferred estimates. The attenuation of the ATT from −2.1 (TWFE) to −1.1 (CS) may reflect this issue, and the event study shows inconsistent signs after 2020. The authors should either (a) focus the main causal claim on Scotland alone and treat Wales as an auxiliary robustness check, or (b) develop a more explicit model separating COVID effects from MUP (e.g., via interaction with national COVID intensity) so that the Wales estimate is not a noisy contaminant in the pooled ATT.

If further issues are needed, the paper might be unsalvageable due to the combination of the above problems; however, addressing them could render the manuscript acceptable.

---

**Suggestions**

1. **Clarify the Identification Strategy with More Diagnostics**  
   - Provide the raw trend lines for Scotland, Wales, and England in the pre-period to visually show growth rates and level differences. Including a figure with rates per 100,000 and shaded treatment periods would help readers assess whether observed pre-period variation is consistent with parallel trends beyond the F-test.  
   - Report the results of the Rambachan–Roth sensitivity analysis that you mention in the appendix. Specifically, quantify how large a deviation from parallel trends (in terms of allowable slope differences or event-study coefficient bounds) would be needed to nullify the ATT. Presenting this will make the robustness claim more concrete.

2. **Strengthen the Callaway–Sant’Anna and TWFE Comparison**  
   - The CS estimator is noted as the “preferred robustness” but yields a notably smaller effect. Provide the cohort-specific ATTs (Scotland 2018, Wales 2020) with their standard errors, so readers can see the treatment-timing heterogeneity driving the aggregated ATT. Similarly, report the number of never-treated comparisons used for each cohort to assess inference power.  
   - Compare the TWFE and CS estimates in the same table, including placebo units (e.g., in-space placebo where Wales is treated earlier) to demonstrate that the TWFE coefficient is not dominated by post-treatment comparisons between treated units. This will help dispel concerns about TWFE weighting issues.

3. **Revisit Wales’s Role or Model COVID Effects Explicitly**  
   - If Wales remains in the pooled ATT, consider augmenting the TWFE with a COVID interaction (e.g., a Wales × COVID dummy or continuous pandemic severity measure). This could isolate the MUP effect from the pandemic-induced shock, making the comparison to England more credible.  
   - Alternatively, produce an additional panel, parallel to Table 2, that reports the TWFE and CS estimates separately for Scotland-only and Wales-only comparisons. This would allow readers to weigh the Wales evidence separately without conflating it with Scotland’s cleaner signal.

4. **Synthetic Control Explanation**  
   - Provide pre-period MSPE for Scotland and the donor placebos. If Scotland’s MSPE is an order of magnitude larger than any donor, note that explicitly and mention how this compares to typical synthetic control diagnostics.  
   - Discuss whether alternative donor sets (e.g., using lower-tier English authorities with elevated mortality similar to Scotland) could ameliorate the mismatch. If such data are unavailable, explain why the existing donor pool is the best feasible option.

5. **Address Potential Spillovers and Policy Variation**  
   - Explicitly check whether English regions bordering Scotland experienced any anticipatory effects (e.g., increased cross-border purchases) after Scottish MUP. This could be done by estimating a small DiD comparing border regions to non-border regions within England, or by including an interaction term for “bordering Scotland.”  
   - Document any alcohol-related policy changes in England during the sample period (even if they are minor) to reassure readers that the comparison group did not implement offsetting interventions.

6. **Enhance the Deprivation Analysis**  
   - The deprivation gradient table currently uses only select deciles. Provide a figure showing the entire D1–D10 pattern and overlay pre/post periods to visualize how the gradient evolved over time in England.  
   - Clarify whether any decompositions (e.g., Oaxaca-Blinder) link the widening gradient explicitly to price changes or to the absence of MUP. Without such links, the equity argument remains associative rather than causal. Consider referencing existing literature (e.g., NHS studies) that ties deprivation-specific alcohol mortality increases to cheap off-trade products, reinforcing the mechanism.

7. **Improve Interpretation of Absolute Magnitudes**  
   - When translating the per-100,000 rates into deaths averted, provide confidence intervals to reflect statistical uncertainty. For instance, 140 deaths averted per year should be presented with an associated 95% CI derived from the ATT standard error and the Scottish population.  
   - Discuss how mortality reductions might evolve beyond 2023, especially given Scotland’s 2024 increase to 65p per unit. While outside the sample, noting whether a higher floor would plausibly amplify the existing trend could guide future policy.

8. **Document Data and Reproducibility**  
   - Include a brief table in the appendix with data sources, download dates, and any adjustments made (e.g., how Scots and Welsh age-standardized rates were harmonized).  
   - Provide code (or a link to the repository) that replicates the main DiD and event-study estimates, along with processed data files, to enhance transparency and replicability.

By addressing these suggestions—particularly clarifying the synthetic control discrepancy, better separating Wales’s COVID-confounded signal, and reinforcing the parallel-trends justification—the paper would present a more convincing causal narrative that aligns with the stated research question.
